Introduction from Pauline M. Camacho, MD, FACE
The treatment of osteoporosis remains one of the fastest moving areas in endocrinology. There are currently eight FDA approved drugs in the US that are used for managing this disease. Several exciting new agents are on the horizon for the treatment of osteoporosis, specifically a sclerostin inhibitor and a cathepsin K inhibitor. Both have mechanisms of action that are slightly different from existing approved agents.
In this edition of EndoScan, we review data on the two new agents, and a study that evaluated combination therapy with two existing drugs.
We also present the most comprehensive guidelines on the management of postmenopausal osteoporosis from the American Association of Clinical Endocrinologists (published in 2010) and the latest guidelines on the diagnosis and treatment of vitamin D deficiency from the Endocrine Society (published in 2012) to guide our readers in managing these very common bone disorders.